BiochemistryDOI: 10.1021/acs.biochem.4c00371
Tag: Alzheimer’s Disease
Early Testing for Alzheimer’s: What Are The Ethical Costs?
AI SummaryThis article discusses the ethical and financial considerations surrounding early testing for Alzheimer’s disease using blood tests. Ethicist Art Caplan explores the potential costs, both ethical and financial, associated with such tests.Ethicist Art Caplan discusses ethical and financial considerations for new Alzheimer’s detection blood tests. Medscape Business of Medicine
Nighttime Outdoor Light Pollution Linked to Alzheimer’s Risk
A new national study showed the association between AD risk and nighttime light pollution was seen across subgroups, with younger people particularly vulnerable. Medscape Medical News
[ASAP] Quinazolinone–Hydrazine Cyanoacetamide Hybrids as Potent Multitarget-Directed Druggable Therapeutics against Alzheimer’s Disease: Design, Synthesis, and Biochemical, In Silico, and Mechanistic Analyses
AI SummaryThis article discusses the design, synthesis, and analysis of Quinazolinone-Hydrazine Cyanoacetamide hybrids as potential therapeutics for Alzheimer’s disease. The study includes biochemical, in silico, and mechanistic analyses to determine the effectiveness of these compounds as multitarget-directed drugs. The research focuses on developing drugs that can target multiple pathways involved in Alzheimer’s disease to provide… Continue reading [ASAP] Quinazolinone–Hydrazine Cyanoacetamide Hybrids as Potent Multitarget-Directed Druggable Therapeutics against Alzheimer’s Disease: Design, Synthesis, and Biochemical, In Silico, and Mechanistic Analyses
Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease
Microglial activation is one hallmark of Alzheimer disease (AD) neuropathology but the impact of the regional interplay of microglia cells in the brain is poorly understood. We hypothesized that microglial act…
Sex-Dependent Synaptic Alterations in a Mouse Model of Alzheimer’s Disease
ERRα and ERRγ coordinate expression of genes associated with Alzheimer’s disease, inhibiting DKK1 to suppress tau phosphorylation
Athira Pharma’s Alzheimer’s Drug Fails in Mid-to-late Stage Trial
Athira Pharma said on Tuesday its drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer’s disease. Reuters Health Information
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration
AI SummaryThis study explores the frequency and neuroanatomic correlates of itching in patients with frontotemporal lobar degeneration spectrum disorders and Alzheimer’s disease. It aims to understand the characteristics of itching with undetermined origin through research visit summaries and magnetic resonance images. The findings could provide valuable insights into the neurological aspects of itching in these… Continue reading Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration
p-Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation
AI SummaryThis study examines the use of plasma markers p-tau217 and Aβ42/40 to predict the onset of Alzheimer’s disease-related Aβ pathology in individuals without cognitive impairment and low brain Aβ levels. The research focuses on the potential of these markers to identify early brain Aβ accumulation.This cohort study investigates the utility of plasma markers phosphorylated… Continue reading p-Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation